Charles River Laboratories International Stock Price Target and Analyst Ratings (NYSE:CRL)

Analyst Price Target for CRL

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$241.56

▼ -15.42% Downside Potential

This price target is based on 16 analysts offering 12 month price targets for Charles River Laboratories International in the last 3 months. The average price target is $241.56, with a high forecast of $350.00 and a low forecast of $145.00. The average price target represents a -15.42% upside from the last price of $285.61.

Buy

The current consensus among 16 investment analysts is to buy stock in Charles River Laboratories International. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
12 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

9/5/2019

0 strong buy ratings
10 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

12/4/2019

1 strong buy ratings
13 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

3/3/2020

1 strong buy ratings
15 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

6/1/2020

1 strong buy ratings
14 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

8/30/2020

1 strong buy ratings
14 buy ratings
2 hold ratings
0 sell ratings

Ratings as of

11/28/2020

1 strong buy ratings
13 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

1/27/2021

0 strong buy ratings
12 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

2/26/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
2/25/2021	Deutsche Bank Aktiengesellschaft	Boost Price Target	Buy	$250.00 ➝ $334.00	Medium	i
2/25/2021	Morgan Stanley	Boost Price Target	Overweight	$280.00 ➝ $350.00	Medium	i
2/18/2021	Truist	Boost Price Target		$256.00 ➝ $324.00	Medium	i
2/18/2021	Credit Suisse Group	Boost Price Target	Neutral	$259.00 ➝ $301.00	High	i
2/18/2021	Deutsche Bank Aktiengesellschaft	Boost Price Target	Buy	$250.00 ➝ $334.00	High	i
12/22/2020	Argus	Boost Price Target	Buy	$235.00 ➝ $265.00	Low	i
12/16/2020	Smith Barney Citigroup	Downgrade	Buy ➝ Neutral		Low	i
12/16/2020	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Downgrade	Buy ➝ Neutral	$270.00 ➝ $250.00	N/A	i
11/24/2020	KeyCorp	Boost Price Target	Overweight	$233.00 ➝ $256.00	High	i
11/3/2020	Truist	Boost Price Target		$237.00 ➝ $256.00	Low	i
10/30/2020	Morgan Stanley	Boost Price Target	Overweight	$245.00 ➝ $260.00	Medium	i
10/30/2020	Deutsche Bank Aktiengesellschaft	Boost Price Target	Buy	$235.00 ➝ $250.00	Medium	i
9/14/2020	Argus	Boost Price Target	Buy	$190.00 ➝ $235.00	Low	i
9/10/2020	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$213.00 ➝ $254.00	High	i Rating by David Windley at Jefferies Financial Group Inc.
8/18/2020	KeyCorp	Boost Price Target	Overweight	$186.00 ➝ $233.00	Low	i
8/6/2020	Morgan Stanley	Boost Price Target	Overweight	$175.00 ➝ $245.00	Low	i
8/6/2020	Citigroup	Boost Price Target	Buy	$190.00 ➝ $255.00	Low	i
7/21/2020	UBS Group	Boost Price Target	Buy	$200.00 ➝ $236.00	Low	i
7/1/2020	Bank of America	Upgrade	Neutral ➝ Buy	$192.00	Low	i
5/26/2020	Argus	Boost Price Target	Average ➝ Buy	$150.00 ➝ $190.00	Medium	i
5/13/2020	UBS Group	Upgrade	Neutral ➝ Buy	$177.00 ➝ $200.00	Low	i
5/12/2020	Deutsche Bank Aktiengesellschaft	Lower Price Target	Buy	$190.00 ➝ $174.00	Medium	i
5/8/2020	JPMorgan Chase & Co.	Boost Price Target	Overweight	$160.00 ➝ $180.00	Low	i
5/8/2020	Robert W. Baird	Boost Price Target	Outperform	$156.00 ➝ $175.00	Low	i Rating by Eric Coldwell at Robert W. Baird
5/8/2020	Credit Suisse Group	Lower Price Target	Neutral	$162.00 ➝ $159.00	Low	i
5/8/2020	Morgan Stanley	Boost Price Target	Overweight	$152.00 ➝ $175.00	Medium	i
5/8/2020	Citigroup	Boost Price Target	Buy	$165.00 ➝ $190.00	Medium	i
5/8/2020	SunTrust Banks	Boost Price Target	Buy	$130.00 ➝ $194.00	Medium	i
4/21/2020	Jefferies Financial Group	Downgrade	Buy ➝ Hold	$139.00	High	i
4/9/2020	Citigroup	Lower Price Target	Buy	$200.00 ➝ $165.00	Medium	i
4/6/2020	SunTrust Banks	Boost Price Target	Buy	$124.00 ➝ $130.00	High	i
3/30/2020	Wells Fargo & Company	Lower Price Target	Overweight	$200.00 ➝ $145.00	High	i
3/27/2020	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$152.00	High	i
3/26/2020	Barclays	Lower Price Target	Equal Weight	$170.00 ➝ $154.00	High	i
3/23/2020	Jefferies Financial Group	Lower Price Target	Buy	$200.00 ➝ $139.00	Medium	i
3/17/2020	SunTrust Banks	Lower Price Target	Buy	$188.00 ➝ $124.00	High	i
3/2/2020	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy	$190.00	High	i
2/18/2020	Wolfe Research	Upgrade	Peer Perform ➝ Outperform	$169.00 ➝ $203.00	Low	i
2/12/2020	Morgan Stanley	Boost Price Target	Equal Weight	$156.00 ➝ $176.00	Medium	i
2/12/2020	Robert W. Baird	Reiterated Rating	Outperform	$165.00 ➝ $185.00	Medium	i
2/12/2020	Barclays	Reiterated Rating	Hold	$170.00	Low	i
2/12/2020	Citigroup	Boost Price Target	Buy	$185.00 ➝ $200.00	Low	i
2/11/2020	Cfra	Boost Price Target	Strong-Buy	$165.00 ➝ $180.00	Medium	i
1/10/2020	The Goldman Sachs Group	Upgrade	Neutral ➝ Buy	$143.00 ➝ $179.00	Low	i
1/7/2020	Wells Fargo & Company	Initiated Coverage	Overweight	$180.00	Low	i
1/6/2020	Citigroup	Initiated Coverage	Buy	$185.00	Low	i
12/17/2019	Robert W. Baird	Boost Price Target	Outperform	$160.00 ➝ $165.00	Medium	i
12/9/2019	KeyCorp	Boost Price Target	Overweight ➝ Overweight	$151.00 ➝ $162.00	Medium	i
11/19/2019	Argus	Reiterated Rating	Buy	$170.00	Low	i
10/18/2019	Bank of America	Downgrade	Buy ➝ Neutral	$150.00	High	i
9/16/2019	SunTrust Banks	Boost Price Target	Buy ➝ Buy	$156.00 ➝ $162.00	Medium	i
9/13/2019	Credit Suisse Group	Set Price Target	Hold	$138.00	Medium	i Rating by Erin Wright at Credit Suisse Group AG
6/10/2019	SVB Leerink	Initiated Coverage	Outperform	$155.00	Low	i Rating by D. Larsen at SVB Leerink LLC
4/30/2019	Evercore ISI	Reiterated Rating	Outperform ➝ Outperform	$160.00	Low	i
4/2/2019	Wolfe Research	Initiated Coverage	Market Perform		Medium	i
3/18/2019	Barclays	Boost Price Target	Equal Weight ➝ Equal Weight	$135.00 ➝ $145.00	Medium	i
3/11/2019	KeyCorp	Boost Price Target	Overweight ➝ Overweight	$140.00 ➝ $151.00	Low	i
2/14/2019	Barclays	Reiterated Rating	Hold	$135.00	Low	i
2/14/2019	SunTrust Banks	Boost Price Target	Positive ➝ Buy	$151.00	Low	i
2/14/2019	Jefferies Financial Group	Reiterated Rating	Buy	$162.00	Low	i
12/14/2018	Deutsche Bank Aktiengesellschaft	Initiated Coverage	Buy ➝ Buy		Low	i
12/4/2018	Raymond James	Reiterated Rating	Buy	$150.00	Low	i Rating by Michael J. Baker at Raymond James
12/3/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Equal Weight	$112.00 ➝ $136.00	Low	i Rating by Ricky Goldwasser at Morgan Stanley
11/8/2018	Robert W. Baird	Boost Price Target	Outperform ➝ Outperform	$144.00 ➝ $148.00	Medium	i
11/8/2018	Raymond James	Boost Price Target	Outperform ➝ Buy	$140.00 ➝ $150.00	Medium	i Rating by Michael J. Baker at Raymond James
11/7/2018	Royal Bank of Canada	Set Price Target	Outperform ➝ Buy	$131.00 ➝ $147.00	N/A	i Rating by George Hill at Royal Bank of Canada
10/9/2018	UBS Group	Initiated Coverage	Neutral ➝ Neutral	$140.00	Low	i
9/25/2018	Credit Suisse Group	Boost Price Target	Neutral ➝ Neutral	$121.00 ➝ $128.00	High	i
9/17/2018	Robert W. Baird	Boost Price Target	Outperform	$133.00 ➝ $141.00	Low	i
9/11/2018	Morgan Stanley	Boost Price Target	Equal Weight ➝ Hold	$102.00 ➝ $112.00	Low	i Rating by Ricky Goldwasser at Morgan Stanley
8/27/2018	Argus	Boost Price Target	Buy ➝ Buy	$125.00 ➝ $140.00	Low	i
8/23/2018	Raymond James	Upgrade	Market Perform ➝ Outperform	$140.00	Medium	i
8/21/2018	Credit Suisse Group	Lower Price Target	Neutral ➝ Neutral	$129.00 ➝ $121.00	Low	i
8/9/2018	Barclays	Boost Price Target	Equal Weight ➝ Equal Weight	$110.00 ➝ $120.00	Medium	i
8/9/2018	Jefferies Financial Group	Boost Price Target	Buy ➝ Buy	$140.00 ➝ $145.00	High	i
8/9/2018	SunTrust Banks	Boost Price Target	Buy	$135.00	Medium	i
7/20/2018	Jefferies Financial Group	Reiterated Rating	Buy	$140.00	Low	i
7/17/2018	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$131.00	High	i Rating by George Hill at Royal Bank of Canada
7/16/2018	Bank of America	Boost Price Target	Buy ➝ Buy	$120.00 ➝ $125.00	Low	i
6/15/2018	KeyCorp	Upgrade	Sector Weight ➝ Overweight	$115.85 ➝ $130.00	High	i
4/20/2018	Mitsubishi UFJ Financial Group	Initiated Coverage	Neutral	$115.00	Low	i Rating by J. Twizell at Mitsubishi UFJ Financial Group
3/14/2018	Morgan Stanley	Reiterated Rating	Equal Weight ➝ Equal Weight	$94.00 ➝ $102.00	Low	i
2/16/2018	Barclays	Reiterated Rating	Hold	$110.00	Low	i
2/15/2018	Credit Suisse Group	Reiterated Rating	Hold	$108.00	Low	i
2/14/2018	JPMorgan Chase & Co.	Boost Price Target	Overweight ➝ Overweight	$110.00 ➝ $120.00	Medium	i
2/14/2018	SunTrust Banks	Upgrade	Hold ➝ Buy	$107.66 ➝ $125.00	Medium	i
2/13/2018	Royal Bank of Canada	Set Price Target	Hold	$116.00	High	i Rating by George Hill at Royal Bank of Canada
2/13/2018	Robert W. Baird	Set Price Target	Buy	$123.00	High	i Rating by Eric Coldwell at Robert W. Baird
1/22/2018	SunTrust Banks	Downgrade	Buy ➝ Hold	$107.89 ➝ $111.00	Medium	i
1/18/2018	Evercore ISI	Initiated Coverage	In ➝ In-Line	$117.00	Low	i
12/13/2017	Argus	Initiated Coverage	Buy ➝ Buy	$120.00	Medium	i
11/17/2017	SunTrust Banks	Reiterated Rating	Buy	$113.00	N/A	i
11/13/2017	Robert W. Baird	Set Price Target	Buy	$117.00	N/A	i
11/10/2017	Bank of America	Lower Price Target	Buy	$117.00 ➝ $115.00	N/A	i
10/16/2017	Credit Suisse Group	Reiterated Rating	Neutral	$95.00 ➝ $112.00	N/A	i
10/9/2017	Jefferies Financial Group	Boost Price Target	Buy	$120.00 ➝ $130.00	N/A	i
9/19/2017	Royal Bank of Canada	Initiated Coverage	Sector Perform ➝ Sector Perform	$110.00	Medium	i
9/12/2017	Jefferies Financial Group	Reiterated Rating	Buy	$120.00	Low	i
9/1/2017	Robert W. Baird	Reiterated Rating	Buy	$114.00	Low	i
7/19/2017	Barclays	Reiterated Rating	Hold	$102.00	Low	i Rating by Jack Meehan at Barclays PLC
6/30/2017	Jefferies Financial Group	Reiterated Rating	Buy	$121.00	Low	i
6/28/2017	Citigroup	Reiterated Rating	Neutral	$91.00 ➝ $104.00	Low	i
6/14/2017	Jefferies Financial Group	Reiterated Rating	Buy		Low	i
6/6/2017	Credit Suisse Group	Reiterated Rating	Neutral	$89.00 ➝ $95.00	Low	i
5/13/2017	Barclays	Set Price Target	Hold	$90.00	Low	i Rating by Jack Meehan at Barclays PLC
5/11/2017	Citigroup	Reiterated Rating	Neutral	$90.00 ➝ $104.00	Low	i
4/21/2017	Jefferies Financial Group	Reiterated Rating	Buy	$106.00	Low	i
3/16/2017	Jefferies Financial Group	Reiterated Rating	Buy		High	i
2/15/2017	UBS Group	Boost Price Target		$84.00	N/A	i
2/15/2017	Jefferies Financial Group	Boost Price Target	Buy	$104.00	N/A	i
1/4/2017	Evercore ISI	Upgrade	Hold ➝ Buy	$86.50	N/A	i
12/20/2016	Jefferies Financial Group	Reiterated Rating	Buy	$93.00	N/A	i
12/16/2016	The Goldman Sachs Group	Upgrade	Sell ➝ Neutral	$75.00 ➝ $77.00	N/A	i
11/30/2016	Barclays	Upgrade	Underweight ➝ Equal Weight	$65.00 ➝ $77.00	N/A	i
11/18/2016	Bank of America	Set Price Target	Buy	$93.00	N/A	i
9/30/2016	Credit Suisse Group	Reiterated Rating	Hold ➝ Neutral		N/A	i Rating by Erin Wilson at Credit Suisse Group AG
9/6/2016	UBS Group	Downgrade	Neutral ➝ Sell	$83.00 ➝ $78.00	N/A	i
8/4/2016	Evercore ISI	Reiterated Rating	Hold	$83.50 ➝ $91.50	N/A	i
8/4/2016	Jefferies Financial Group	Boost Price Target	Buy	$94.00 ➝ $100.00	N/A	i
8/4/2016	Citigroup	Boost Price Target	Neutral	$85.00 ➝ $90.00	N/A	i
6/20/2016	Credit Suisse Group	Initiated Coverage	Neutral	$84.00	N/A	i
5/22/2016	KeyCorp	Reiterated Rating	Hold	$77.00	N/A	i
5/20/2016	Barclays	Boost Price Target	Underweight	$60.00 ➝ $65.00	N/A	i
5/5/2016	UBS Group	Reiterated Rating	Neutral	$76.00 ➝ $83.00	N/A	i
4/26/2016	Gabelli	Initiated Coverage	Buy	$96.00	N/A	i Rating by S. Wojda at Gabelli

(Data available from 2/26/2016 forward)

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as bioanalysis, drug metabolism, pharmacokinetics, safety pharmacology, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company has a strategic partnership with PathoQuest SAS to establish a next generation sequencing based testing laboratory. Charles River Laboratories International, Inc. is based in Wilmington, Massachusetts.

Today's Range

Now: $285.61

$278.02

$285.90

50 Day Range

MA: $276.82

$252.87

$299.48

52 Week Range

Now: $285.61

$95.58

$303.79

Volume

2,406 shs

Average Volume

340,319 shs

Market Capitalization

$14.22 billion

P/E Ratio

47.60

Dividend Yield

N/A

Beta

1.12

Frequently Asked Questions

What sell-side analysts currently cover shares of Charles River Laboratories International?

The following sell-side analysts have issued research reports on Charles River Laboratories International in the last year: Argus, Bank of America Co., Barclays PLC, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group Inc., JPMorgan Chase & Co., KeyCorp, Morgan Stanley, Robert W. Baird, Smith Barney Citigroup, SunTrust Banks, Inc., Truist, UBS Group AG, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for CRL.

What is the current price target for Charles River Laboratories International?

16 Wall Street analysts have set twelve-month price targets for Charles River Laboratories International in the last year. Their average twelve-month price target is $241.56, suggesting a possible downside of 13.8%. Morgan Stanley has the highest price target set, predicting CRL will reach $350.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $145.00 for Charles River Laboratories International in the next year.
View the latest price targets for CRL.

What is the current consensus analyst rating for Charles River Laboratories International?

Charles River Laboratories International currently has 4 hold ratings and 12 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CRL will outperform the market and that investors should add to their positions of Charles River Laboratories International.
View the latest ratings for CRL.

What other companies compete with Charles River Laboratories International?

Other companies that are similar to Charles River Laboratories International include Thermo Fisher Scientific, Illumina, Agilent Technologies, Mettler-Toledo International, Bio-Rad Laboratories, Waters, Bio-Techne, PerkinElmer, Bruker, Pacific Biosciences of California, Luminex, Fluidigm, Harvard Bioscience, aTyr Pharma and BG Medicine.

How do I contact Charles River Laboratories International's investor relations team?

Charles River Laboratories International's physical mailing address is 251 BALLARDVALE STREET, WILMINGTON MA, 01887. The medical research company's listed phone number is 781-222-6000 and its investor relations email address is [email protected] The official website for Charles River Laboratories International is www.criver.com.

NYSE:CRL - Charles River Laboratories International Stock Price Target and Predictions

Analyst Price Target for CRL

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Charles River Laboratories International?

What is the current price target for Charles River Laboratories International?

What is the current consensus analyst rating for Charles River Laboratories International?

What other companies compete with Charles River Laboratories International?

How do I contact Charles River Laboratories International's investor relations team?